Marina Baretti, MD

Marina Baretti, MD, discussed the potential utilization of tissue-free ctDNA monitoring for early recurrence detection and treatment monitoring in CCA.

Marina Baretti, MD, on results from a phase 2 study of entinostat in combination with nivolumab for the treatment of advanced pancreatic ductal adenocarcinoma.

Marina Baretti, MD, discusses some common adverse effects associated with FGFR inhibition in patients with cholangiocarcinoma, as well as strategies to mitigate these AEs in clinical practice.

Marina Baretti, MD, discusses innate and acquired mechanisms of resistance in patients with unresectable, advanced, or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or rearrangements.

Marina Baretti, MD, discusses the evolving utility of FGFR inhibitors in the treatment of patients with unresectable, advanced, or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.